Clinical Research at SWFT

Introduction to clinical research at SWFT

At South Warwickshire University NHS Foundation Trust, we are committed to operating a dynamic programme of clinical research to pave the way for new approaches to treatment and care.

Clinical research is a vital means of developing these new approaches to patient treatment and care for a wide range of illnesses and conditions. It allows us to assess the efficacy of new medicines, treatments and diagnostic regimes, providing evidence we can use to benefit patients. We operate an evolving programme of research studies that have great potential to create long-term improvements for patients everywhere. Through our research studies the team is also able to deliver immediate improvements for the patients that have volunteered to take part in them.

We currently undertake a wide range of studies ranging from simple questionnaires to drug trials at Warwick Hospital, Leamington Spa Rehabilitation Hospital and Stratford Hospital. Patients may be invited to take part in a clinical study whilst they are treated at the hospital.

Our Research team also works closely with national and local organisations concerned with developing these new approaches to patient treatment and care.

What are we working on at the moment?

We currently have several clinical trials in operation. Click the tabs below to find out more information. A number of these are focused on developing new approaches to treating certain types of cancer.

We’re currently developing the information we have about our research programme on our website, and will be posting more information and insights into the programme on this page in the coming weeks and months.

In the meantime, if you have any questions about the work we’re doing, you can email us at research@swft.nhs.uk.

Staff Information

Research Governance

Associate Medical Director of Research

Head of Research & Development

Email: Research@swft.nhs.uk Twitter: @Research_SWFT

Core Research

Senior Research Nurse

Email: Research.Nurses@swft.nhs.uk

Cancer Research

Rigby Lead Nurse – Cancer Research

Email: cancerresearch@swft.nhs.uk Twitter: @CancerWarwick

Family Health Research

Lead Research Midwife

Email: ResearchMidwife@swft.nhs.uk

Cancer Studies

Oncology and Haematology Trials

The clinical benefit of undertaking cancer research includes access to the most novel and innovative cancer therapies. It has led to new drug treatments, a greater understanding of how to prevent cancer, new ways of delivering treatments and new surgical techniques. Cancer clinical trials are critical to advances in the understanding and treatment of cancer and to ensure patients have the opportunity to access world-class cancer treatments.

There is evidence to suggest that clinical research activity is a driver for high-quality cancer care with better outcomes for patients who are treated in research-intensive hospitals (National Institute for Health Research, 2014).

We have highlighted three of our current trials below:

Tropion.PNG

TROPION-Breast02 is recruiting patients with previously untreated triple negative breast cancer (TNBC) that has spread (metastatic) or TNBC that has come back and cannot be removed. This international AstraZeneca Phase III study is assessing whether a new treatment, datopotamab deruxtecan (Dato-DXd), is better than current treatments. TNBC affects 1 in 5 women with breast cancer and is more common in women <40 and black women. It is the most aggressive type of breast cancer and cannot be treated with hormonal or targeted therapies. The outcome for patients with metastatic TNBC is usually worse than other types of breast cancer, with overall survival generally less than two years and five-year survival around 12%. Current treatment options may be poorly tolerated by patients and reduce quality of life. Dato-DXd is an antibody-drug conjugate, a treatment that can target breast cancer cells and deliver a drug that stops the cells growing. Warwick Hospital is offering the promising new treatment to patients across The Midlands.

Radar.PNG

Myeloma XV (RADAR) is recruiting patients newly diagnosed with Multiple Myeloma (MM) who are able to have a stem cell transplant. MM, also known as Myeloma, is a cancer that affects the bone marrow, spongy tissue found inside some bones that produces blood cells. Over 5,500 patients are diagnosed with MM each year in the UK. MM is an incurable relapsing-remitting cancer, meaning there are periods where the disease is active (relapsing) and requires treating, followed by periods where treatment may not be required (remitting). Significant progress has been made in developing new lines of treatment over the past 15 years. Newly diagnosed patients now survive on average 5-6 years, with 37% of men and 28% of women surviving 10 years. Currently all MM patients are given the same treatment, this UK-based Phase III study is investigating the personalisation of MM care. Some patients will have genetic markers that suggest their cancer will be more difficult to treat. These higher-risk patients, along with those whose cancer has not responded well to initial treatment, are offered more intensive therapy to extend the remitting period, while lower risk patients can receive reduced treatment with the aim of reducing side effects.

Mithradate.PNG

Mithridate is recruiting patients with polycythemia vera (PV) who are at high risk of blood clots and their disease becoming a more serious blood cancer. PV is a rare slow-growing blood cancer where the bone marrow (spongy tissue found inside some bones) makes too many blood cells, this causes the blood to be thicker than normal. PV patients can experience tiredness, itching, blood clots, and bleeding. In some cases, PV can also transform into more serious blood cancers, such as leukaemia. High-risk patients on average survive 11 years. This international Phase III study is assessing whether a new treatment, ruxolitinib, is able to reduce the number of complications and risk of PV becoming a more serious cancer when compared with the current best available therapies (hydroxycarbamine or interferon α). Ruxolitinib is a targeted immunotherapy that switches off the mutated gene that causes the overproduction of blood cells in PV.

We are also recruiting to the following trials: Cutaneous Tumour, Nerlyfe, Rampart, Rudy, Stampede, TransRampart, UKGPCS and UKAITPR. For more information visit Be Part of Research or contact us directly.

Family Health


GBS3 trial is looking at whether testing pregnant women for Group B Streptococcus reduces the risk of infection in newborn babies compared to the current strategy in place in the UK. The current strategy in the UK is to offer antibiotics during labour to women who are considered at raised risk of their baby developing a group B Strep infection.

There are two different tests, which the study is comparing against the current strategy. Hospitals are randomly allocated to 1 of 3 groups:

  • Lab Based Test at 3-5 weeks before anticipated delivery date (Enriched Culture Medium Testing)
  • Bedside Test at start of labour (Intrapartum Rapid Testing)
  • Risk Factor Based testing (Usual Care)

SWFT has been randomised to the Risk Factor Based testing group. This means no additional procedures (outside of the usual care) will be undertaken. Women will be treated for group B Strep in accordance with SWFT hospital policy and the current UK strategy.


The Giant PANDA Trial is looking at evaluating the effects of different antihypertensive drugs in women with pregnancy hypertension on maternal and foetal/neonatal outcomes.

The study is a randomised control trial, which means women who want to take part are randomised into one of two medication groups, both of which can be used to treat raised blood pressure in pregnancy.

The aim of the trial is to identify which is the most suitable medication to use, therefore the Research Midwife team at SWFT will follow the participant’s pregnancy and birth, providing anonymised data to the trial team. If the medication that the participant is randomised to isn’t working to treat their raised blood pressure, they can be reverted back to the alternative medication.

CRAFT-OBS is a study run by Kings College London. The aim of the study is to understand the association between the degree of cervical dilatation at caesarean section in labour, with the risk of late miscarriage or pre-term birth in subsequent pregnancies.

Women who are less than 37 weeks pregnant and who have had a previous term caesarean section in labour are invited to participate in this observational study.

Data around pregnancy and birth of these women is collected by the SWFT Research Midwife team and anonymised on the national database, to help the study team identify if there is an association between previous caesarean sections in labour and preterm birth in a future pregnancy.

Core Research

PQIP_Logo.jpgPerioperative Quality Improvement Programme (PQIP)

PQIP is a national research and quality improvement initiative which is looking at the perioperative care of patients having elective surgery. The aim is to investigate how these patients are treated, how they feel their care and recovery has been and if any complications have occurred. This data can then be used to improve patient care and ensure best practice is maintained throughout the whole country.

Here at Warwick Hospital, we have successfully recruited over 250 colorectal patients to the study.

For more information go to www.pqip.org.uk


SQUEEZE_Logo.jpg


SQUEEZE-UK

The SQUEEZE-UK study

In June 2022 we opened the SQUEEZE-UK study. This study is looking at postoperative use of a medication type (vasopressor) to maintain a patient’s blood pressure and the relation to developing atrial fibrillation (AF) an irregular heart rhythm.

Some patients during surgery develop abnormally low blood pressure, sometimes requiring the need of a vasopressor medication. This often leads to an intensive care stay and possibly prolonged hospital stay leading to increased risks of developing complications.

This is a two part study, cohort A data collection of all non-day case surgical patients taking place as a “snapshot” over 7 consecutive days this will help determine the proportion of patients receiving vasopressors and developing AF.

Cohort B will recruit a further 30 patients who develop low blood pressure and require vasopressors with a more in-depth data collection.

To date we have recruited 85 patients in Cohort A and 19 patients for Cohort B.

SQUEEZE-UK will then be analysed as part of the worldwide SQUEEZE study

Optimise_Logo.png

OPTIMISE Study

Research Question: Can we predict which patients with Psoriatic Arthritis will respond to treatment using precision medicine?

This study is supporting patients with Psoriatic Arthritis who do not respond to standard arthritis drugs. There are two different types of biologic drugs available (Adalimumab and Secukinumab).

In patients taking either of these drugs about 50 % will find the drug relieves their symptoms, however importantly 50 % will not respond well. Trying each drug can take time and patients have to wait to see if another drug works.

We do not currently know how to predict in advance which patient will respond best to each drug. The study aim is to test whether we can predict, using blood tests, if people with Psoriatic Arthritis will respond to either biologic drug leading to a reduction in inflamed joints and pain.